前臨床CRO市場：サービス、用途、エンドユーザー別-2024-2030年の世界予測

前臨床CRO市場規模は2023年に62億5,000万米ドルと推定され、2024年には68億5,000万米ドルに達し、CAGR 9.68％で2030年には119億5,000万米ドルに達すると予測されます。

前臨床CROは、動物実験を通して医薬品候補を臨床段階に導くために不可欠な研究開発活動（R&D）の専門知識を提供するサポートセンターです。前臨床試験サービスには、動物モデルにおける薬剤の有効性と安全性を評価し、治験薬（IND）申請を行うために重要ないくつかの試験が含まれます。前臨床試験においてCROは、バイオ製薬会社などのスポンサーに雇われ、スポンサーに代わって様々な技術的・管理的責任を負いながら、一連の業務を遂行します。前臨床段階にある医薬品の数が急増し、医薬品開発のための研究開発（R&D）予算が増加していることが、前臨床CROサービスの利用を促進しています。しかし、前臨床CROサービスには高いコストと時間のかかるプロセスが伴うため、市場成長の妨げとなっています。ハイスループット・スクリーニングやインシリコ・モデリングを含む技術の進歩により、より効率的で費用対効果の高い前臨床研究が可能になり、市場成長の機会が生まれると期待されています。

サービス安全性と規制遵守の側面に焦点を当てた毒性試験サービスの利用が急増

バイオアナリシスおよびDMPK試験は、潜在的な治療薬の吸収・分布・代謝・排泄（ADME）特性を理解する上で極めて重要です。このセグメントは、生物学的システムにおける薬物の挙動に関する重要な情報を提供し、投与量の決定や安全性の評価に最も重要です。これらの研究は、薬剤の薬物動態プロファイルに関する詳細な洞察が必要とされる薬剤開発の初期段階で優先的に実施されます。製薬会社やバイオテクノロジー企業は、生物分析手法や最先端技術の専門知識を持つ外部のCROに頼ることが多いです。毒性試験サービスは、医薬品候補の安全性プロファイルを評価するために不可欠であり、さらなる開発とヒトへの摂取に対する安全性を保証します。この分野では、化合物の生体に対する潜在的な有害作用を評価するための様々な試験が行われます。これらの試験は、臨床試験に進む前に非常に重要であり、主に医薬品が承認されるために通過しなければならない規制要件に対応しています。自社製品が無毒であることを証明する必要があるすべての製薬会社やバイオテクノロジー企業にとって不可欠なものです。

エンドユーザー：バイオ製薬企業による前臨床CROの利用拡大

バイオ製薬会社は、前臨床CROの主要な顧客であり、生物学的製剤の開発・試験にサービスを活用しています。これらの企業は、薬理学、毒物学、分子生物学の専門知識を利用するためにCROとの提携を求めています。バイオ医薬品企業に提供されるサービスには、薬効・安全性評価、吸収・分布・代謝・排泄（ADME）試験、薬事サポートなどが含まれることが多いです。前臨床CROとのコラボレーションにより、バイオ医薬品企業は医薬品開発プロセスを加速し、コストを効果的に管理し、複雑な規制要件を効率的に乗り切ることができます。政府機関や学術機関は、公衆衛生を目的とした研究開発のために前臨床CROと提携しています。これらのパートナーシップは、新薬の発見、ワクチン開発、革新的な治療法などのプロジェクトをサポートしています。前臨床CROは、社内にない専門的なリソースや専門知識へのアクセスをこれらの機関に提供します。さらにCROは、画期的な医学的進歩につながる高品質で規制に準拠した調査研究の実施を支援します。政府/学術機関とCROのコラボレーションは、基礎研究と臨床応用のギャップを埋める上で極めて重要です。医療機器メーカーは、臨床試験に進む前に、製品の安全性と有効性を検証するために前臨床CROのサービスを利用しています。これらの企業は、包括的な生物医学的試験、生体力学的評価、リスク評価を実施するためのCROの技術的・規制的専門知識から利益を得ています。医療機器企業に合わせたサービスには、前臨床試験のデザイン、プロトタイプ試験、国際規格や規制への準拠サポートなどが含まれることが多いです。CROと提携することで、医療機器企業は自社製品が最高の品質と安全基準を満たすことを保証でき、臨床段階への移行がスムーズになります。

地域別の洞察

老年人口における非伝染性疾患のかつてない増加や、公害や昆虫の侵入など環境条件の変化によって引き起こされる伝染性疾患は、ヘルスケア分野における効果的な医薬品開発の需要を生み出し、その結果、アジア太平洋、EMEA全域で前臨床CROサービスの必要性が高まっています。アジア太平洋地域の政府が医療機器や医薬品開発の研究開発（R&D）活動を推進するために行っている投資は、前臨床CRO市場のプレーヤーに成長機会を提供すると推定されます。2021年8月、オーストラリア政府は医療イノベーションと研究プロジェクトに7,900万米ドルを投資しました。欧州連合（EU）の新興経済諸国は、新技術や医薬品開発の研究・イノベーションを優先することで、技術進歩を後押しする政府の支援体制を確立しています。政府は、開発される医薬品や機器が安全で信頼性が高く、高品質であることを保証するために、いくつかの厳しい規制や基準を導入しています。2022年1月、臨床試験プロセスを修正するための臨床試験規則（規則（EU）No 536/2014）がEUで開始されることが決まった。政府は、監督と評価のプロセスを調和させるため、臨床試験情報システム（CTIS）を導入しました。このように、医療機器や医薬品開発のための臨床試験に対する政府の継続的な支援は、EMEAにおける前臨床CRO市場の成長を促進すると予想されます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、前臨床CRO市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、前臨床CRO市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.前臨床CRO市場の市場規模および予測は？

2.前臨床CRO市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.前臨床CRO市場の技術動向と規制枠組みは？

4.前臨床CRO市場における主要ベンダーの市場シェアは？

5.前臨床CRO市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬企業やバイオ医薬品企業による新薬や治療法の開発に向けた研究開発活動の増加
    • 製薬企業による医薬品開発業務のCROへのアウトソーシング増加傾向
    • 個別化医療の開発への注目が高まる
  • 抑制要因
    • 前臨床CROサービスに関連する高コストと時間のかかる制約
  • 機会
    • より効率的で費用対効果の高い前臨床調査を可能にする技術の進歩
    • モノクローナル抗体、ワクチン、細胞療法などの生物製剤の前臨床調査の大きな可能性
  • 課題
    • 国際規制当局が定める厳格な規制とガイドライン
• 市場セグメンテーション分析
  • サービス：安全性と規制遵守の側面に重点を置いた毒性試験サービスの利用が急増
  • エンドユーザー：バイオ医薬品企業による前臨床CROの使用法の進化
• 市場動向分析
  • 南北アメリカでは、確立された製薬・バイオ医薬品企業の存在と、先進的な前臨床CROプラットフォームのイントロダクションが増加しています。
  • アジア太平洋地域における新薬・医療機器の開発に向けた研究開発活動の拡大に対する政府の支援が増加
  • 医薬品開発活動に対する潜在的な政府資金提供により、EMEA地域での前臨床CROビジネスが拡大します。
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 前臨床CRO市場：サービス別

• バイオ分析とDMPK研究
• 毒性試験

第7章 前臨床CRO市場：用途別

• 循環器疾患
• 皮膚科
• 胃腸
• 泌尿器と女性の健康
• 血液学
• 免疫疾患
• 感染症
• 代謝障害
• 神経学
• 腫瘍学
• 眼科
• 呼吸器疾患

第8章 前臨床CRO市場：エンドユーザー別

• バイオ医薬品企業
• 政府機関および学術機関
• 医療機器企業

第9章 南北アメリカの前臨床CRO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の前臨床CRO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの前臨床CRO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • CRO企業TriApex、Legend Capital主導のシリーズC資金調達ラウンドを完了
  • PsychoGenics、新薬発見のためのAI対応プラットフォーム「eCube」を発表
  • プロシア、医薬品の安全性に関する判断を迅速化するために前臨床研究開発を大幅に拡大すると発表
  • AmplifyBioが細胞療法の特性評価を拡大し、前臨床開発のギャップを埋める
  • Clinchoice、CRO買収により事業拡大を継続
  • QPSが台湾に新たな前臨床調査施設を開設
  • CROアバニアがマクシスを買収
  • ApaxがPorsoltの過半数株式を取得し、同社の成長戦略をサポートし、前臨床サービスにおける世界的リーダーとなる
  • クライオポート、細胞・遺伝子治療の推進に向けシネオス・ヘルスとの戦略的提携を発表
  • クラウン・バイオサイエンスとERSジェノミクスがゲノム編集特許に関するCRISPR/Cas9の世界ライセンシング契約を発表
  • ドメイン・セラピューティクスとエクスプリサイトが免疫腫瘍学分野で提携契約を締結
  • セレリオン、初期段階の臨床薬理学ユニットを拡大
  • ClinChoice、シリーズEラウンドで1億5,000万米ドルを調達
  • ヘラ・バイオラボ、チャールズ・リバーとの独占的世界ライセンス契約を発表
  • IonsGate前臨床サービスとInSilicoTrialsが提携

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PRECLINICAL CRO MARKET RESEARCH PROCESS
• FIGURE 2. PRECLINICAL CRO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PRECLINICAL CRO MARKET DYNAMICS
• FIGURE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PRECLINICAL CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOANALYSIS & DMPK STUDIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOANALYSIS & DMPK STUDIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PRECLINICAL CRO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PRECLINICAL CRO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PRECLINICAL CRO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PRECLINICAL CRO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PRECLINICAL CRO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PRECLINICAL CRO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PRECLINICAL CRO MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PRECLINICAL CRO MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PRECLINICAL CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PRECLINICAL CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PRECLINICAL CRO MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PRECLINICAL CRO MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PRECLINICAL CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PRECLINICAL CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PRECLINICAL CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PRECLINICAL CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PRECLINICAL CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PRECLINICAL CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PRECLINICAL CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PRECLINICAL CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GOVERNMENT & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GOVERNMENT & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 68. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 69. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. CANADA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. CANADA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. MEXICO PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 74. MEXICO PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 81. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 88. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 90. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 95. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 96. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 97. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 102. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 103. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. CHINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 106. CHINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 107. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 108. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 109. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. INDIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 112. INDIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 113. INDONESIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 114. INDONESIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 115. INDONESIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. INDONESIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. INDONESIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. INDONESIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 120. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 121. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. JAPAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. JAPAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 126. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 127. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 132. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 133. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 138. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 139. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 144. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 148. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 149. TAIWAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 150. TAIWAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 151. TAIWAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. TAIWAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. TAIWAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. TAIWAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. THAILAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 156. THAILAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 157. THAILAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. THAILAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. THAILAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. THAILAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. VIETNAM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 162. VIETNAM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 163. VIETNAM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. VIETNAM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. VIETNAM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. VIETNAM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 175. DENMARK PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 176. DENMARK PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 177. DENMARK PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. DENMARK PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. DENMARK PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. DENMARK PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. EGYPT PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 182. EGYPT PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 183. EGYPT PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. EGYPT PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. EGYPT PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. EGYPT PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. FINLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 188. FINLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 189. FINLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. FINLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. FINLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. FINLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 194. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 195. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. FRANCE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. FRANCE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 200. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 201. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. GERMANY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. GERMANY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. ISRAEL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 206. ISRAEL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 207. ISRAEL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. ISRAEL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. ISRAEL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. ISRAEL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 212. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 213. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. ITALY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. ITALY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 218. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 219. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 222. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 223. NIGERIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 224. NIGERIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 225. NIGERIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. NIGERIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. NIGERIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 228. NIGERIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 229. NORWAY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 230. NORWAY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 231. NORWAY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. NORWAY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. NORWAY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. NORWAY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. POLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 236. POLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 237. POLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. POLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. POLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. POLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. QATAR PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 242. QATAR PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 243. QATAR PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. QATAR PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. QATAR PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 246. QATAR PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 247. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 248. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 249. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. RUSSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. RUSSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 254. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 255. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 258. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. SPAIN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 266. SPAIN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 267. SPAIN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. SPAIN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. SPAIN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 270. SPAIN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 271. SWEDEN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 272. SWEDEN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 273. SWEDEN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. SWEDEN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. SWEDEN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. SWEDEN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 278. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 279. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. TURKEY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 284. TURKEY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 285. TURKEY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. TURKEY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. TURKEY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. TURKEY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 290. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 291. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 292. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 293. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 294. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 295. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 296. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 297. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 298. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 299. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 300. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 301. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 302. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

[195 Pages Report] The Preclinical CRO Market size was estimated at USD 6.25 billion in 2023 and expected to reach USD 6.85 billion in 2024, at a CAGR 9.68% to reach USD 11.95 billion by 2030.

A preclinical CRO is a support center providing expertise in research and development activities (R&D) essential for navigating a drug candidate through animal testing and forwarding it into the clinical phase. Preclinical research services encompass several studies critical to assessing drug efficacy & safety in animal models and complete Investigational New Drug (IND) filing studies. In a preclinical trial, CROs are hired by sponsors such as biopharma companies to perform a set of tasks, taking various technical and administrative responsibilities on the sponsor's behalf. A surge in the number of drugs in the preclinical phase and an increased research & development (R&D) budget for drug development are driving the usage of preclinical CRO services. The high cost and time-consuming process of preclinical CROS services hamper the market growth. Advances in technology, which include high-throughput screening and in silico modeling, enable more efficient and cost-effective preclinical research and are expected to create opportunities for market growth.

Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects

Bioanalysis and DMPK studies are crucial for understanding potential therapeutic agents' absorption, distribution, metabolism, and excretion (ADME) properties. This segment provides vital information on the drug's behavior in a biological system, which is paramount for dosage determination and safety assessment. These studies are preferred in the early stages of drug development when detailed insight into the drug's pharmacokinetic profile is required. Pharmaceutical companies and biotechnology firms often rely on external CROs with specialized expertise in bioanalytical methodologies and state-of-the-art technologies. Toxicology testing services are vital for evaluating the safety profile of drug candidates, ensuring they are safe for further development and human consumption. This segment encompasses a range of studies to assess the potential adverse effects of compounds on living organisms. These tests are critical before advancing to clinical trials, catering mainly to regulatory requirements that drugs must pass for approval. They are indispensable for all pharmaceutical and biotechnological companies needing to demonstrate the non-toxic nature of their products.

End-User: Evolving usage of preclinical CRO by biopharmaceutical companies

Biopharmaceutical companies are primary clients of preclinical CROs, leveraging their services for the development and testing of biologic drugs. These companies seek CRO partnerships to access specialized expertise in pharmacology, toxicology, and molecular biology. Services offered to biopharmaceutical companies often include drug efficacy and safety assessments, absorption, distribution, metabolism, excretion (ADME) studies, and regulatory support. Collaborating with preclinical CROs enables biopharmaceutical companies to accelerate their drug development process, manage costs effectively, and navigate complex regulatory requirements efficiently. Government and academic institutes often engage with preclinical CROs for research and development initiatives fundamental to public health objectives. These partnerships support projects, including new drug discoveries, vaccine development, and innovative medical treatments. Preclinical CROs provide these institutions with access to specialized resources and expertise that may not be available in-house. Additionally, CROs assist in conducting high-quality, regulatory-compliant research studies that can lead to groundbreaking medical advancements. Collaborations between government / academic institutes and CROs are pivotal in bridging the gap between basic research and clinical application. Medical device companies utilize preclinical CRO services to validate the security and efficacy of their products before proceeding to clinical trials. These companies benefit from CROs' technical and regulatory expertise to conduct comprehensive biomedical testing, biomechanical evaluation, and risk assessment. Services tailored to medical device companies often encompass preclinical study design, prototype testing, and support in complying with international standards and regulations. By partnering with CROs, medical device companies can assure their products meet the highest quality and safety standards, facilitating smoother transitions into clinical phases.

Regional Insights

The unprecedented rise in non-communicable diseases among the geriatric population and communicable diseases caused by changing environmental conditions, such as pollution, and insect infestation, create a demand for effective drug development in the healthcare sector, subsequently increasing the need for preclinical CRO services across the Americas, Asia-Pacific, and EMEA. The investments made by the governments of Asia-Pacific to push research and development (R&D) activities of medical devices and drug development are estimated to provide growth opportunities for the preclinical CRO market players. In August 2021, the Australian government invested USD 79 million in medical innovation and research projects. The developed economies in the European Union have established a supportive government framework to boost technological advancements by prioritizing research and innovation of new technologies and drug development. The government introduces several stringent regulations and standards to ensure that the medicines and devices developed are safe, reliable, and of high quality. In January 2022, the Clinical Trials Regulation (Regulation (EU) No 536/2014) was set to launch in the EU to modify the clinical trial processes. The government introduced a Clinical Trials Information System (CTIS) to harmonize the supervision and assessment processes. Thus, the ongoing government support for clinical trials for medical devices and drug development is expected to fuel the growth of the preclinical CRO market in EMEA.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Preclinical CRO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Preclinical CRO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Preclinical CRO Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., AmplifyBio, Atuka Inc., BenchSci, Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc., Biotrofix, Inc., Celerion, Charles River Laboratories International, Inc., Crown Bioscience, Inc., CTI Clinical Trial and Consulting, Inc., Diag2Tec SAS, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Gubra, Hera Biolabs, ICON PLC, Immusmol SAS, ImQuest BioSciences, Inotiv, Inc., Intertek Group PLC, Invivotek by Genesis Biotechnology Group, LLC, IQVIA Inc., Jubilant Biosys Ltd. byJubilant Pharmova Limited Company, Laboratory Corporation of America Holding, MCI Group Holding SA, MD Biosciences, Medpace Holdings, Inc., Novartis AG, Parexel International Corporation., PharmaCircle LLC, Phenos GmbH, PPD by Thermo Fisher Scientific Inc., PsychoGenics Inc., QPS Holdings, LLC, Sanofi S.A., SCiAN Services Inc., SGS SA, Shanghai Medicilon Inc., Syneos Health, Inc., Transpharmation, Veristat, LLC, Vimta Labs Limited, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preclinical CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Services
  • Bioanalysis & DMPK Studies
  • Toxicology Testing

• Application
  • Cardiovascular Disease
  • Dermatology
  • Gastrointestinal
  • Genitourinary & Women's Health
  • Hematology
  • Immunological Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Neurology
  • Oncology
  • Ophthalmology
  • Respiratory Disorders

• End-User
  • Biopharmaceutical Companies
  • Government & Academic Institutes
  • Medical Device Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Preclinical CRO Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Preclinical CRO Market?

3. What are the technology trends and regulatory frameworks in the Preclinical CRO Market?

4. What is the market share of the leading vendors in the Preclinical CRO Market?

5. Which modes and strategic moves are suitable for entering the Preclinical CRO Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
    • 5.1.1.2. Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
    • 5.1.1.3. Growing focus on the development of personalized medicines
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and time-consuming constraints associated with preclinical CRO services
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing advances in technologies to enable more efficient and cost-effective preclinical research
    • 5.1.3.2. High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and guidelines set by international regulatory authorities
• 5.2. Market Segmentation Analysis
  • 5.2.1. Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects
  • 5.2.2. End-User: Evolving usage of preclinical CRO by biopharmaceutical companies
• 5.3. Market Trend Analysis
  • 5.3.1. Presence of well-established pharmaceutical & biopharmaceutical companies and the rising introduction of advanced preclinical CRO platforms in the Americas
  • 5.3.2. Rising government support for expanding research & development activities into developing new drugs and medical devices in the Asia-Pacific region
  • 5.3.3. Potential government funding in drug development activities expands the preclinical CRO business in the EMEA region.
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis
• 5.8. Client Customization

6. Preclinical CRO Market, by Services

• 6.1. Introduction
• 6.2. Bioanalysis & DMPK Studies
• 6.3. Toxicology Testing

7. Preclinical CRO Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular Disease
• 7.3. Dermatology
• 7.4. Gastrointestinal
• 7.5. Genitourinary & Women's Health
• 7.6. Hematology
• 7.7. Immunological Disorders
• 7.8. Infectious Diseases
• 7.9. Metabolic Disorders
• 7.10. Neurology
• 7.11. Oncology
• 7.12. Ophthalmology
• 7.13. Respiratory Disorders

8. Preclinical CRO Market, by End-User

• 8.1. Introduction
• 8.2. Biopharmaceutical Companies
• 8.3. Government & Academic Institutes
• 8.4. Medical Device Companies

9. Americas Preclinical CRO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Preclinical CRO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Preclinical CRO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
  • 12.3.2. PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
  • 12.3.3. Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
  • 12.3.4. AmplifyBio Expands Cell Therapy Characterization, Fills Gap in Preclinical Development
  • 12.3.5. Clinchoice Continues Expansion with CRO Acquisition
  • 12.3.6. QPS opens an additional preclinical research facility in Taiwan
  • 12.3.7. CRO Avania Acquires MAXIS
  • 12.3.8. Apax Acquires a Majority Stake in Porsolt to Support its Growth Strategy and Become a Global Leader in Preclinical Services
  • 12.3.9. Cryoport Announces Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
  • 12.3.10. Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
  • 12.3.11. Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
  • 12.3.12. Celerion Expands Early Phase Clinical Pharmacology Units
  • 12.3.13. ClinChoice Raises USD 150 Million in Series E Round
  • 12.3.14. Hera BioLabs Announces Exclusive Global License With Charles River
  • 12.3.15. IonsGate Preclinical Services and InSilicoTrials Form Partnership

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio